ABTL0812 + FOLFIRINOX

**ABTL0812 + FOLFIRINOX** is an investigational combination therapy under clinical evaluation for the treatment of advanced (metastatic) pancreatic cancer. - **ABTL0812** is an orally administered small molecule targeting cancer cells primarily via induction of cytotoxic autophagy through two principal mechanisms: inhibition of the Akt/mTORC1 axis by upregulating TRIB3, and induction of endoplasmic reticular stress triggering the Unfolded Protein Response, converging to robust autophagy-mediated cell death. Non-tumoral cells are spared. - **FOLFIRINOX** is an established multi-agent chemotherapy regimen consisting of four drugs: fluorouracil (5-FU, a DNA-synthesis inhibitor), oxaliplatin (a platinum agent interfering with DNA repair), irinotecan (a topoisomerase I inhibitor), and folinic acid (leucovorin, which enhances 5-FU activity). - The combination is designed to exploit the cytotoxic effects of FOLFIRINOX while leveraging ABTL0812’s potential to sensitize cancer cells and target chemoresistant subpopulations. Current trials focus on patients with metastatic pancreatic cancer, with ABTL0812 taken orally and FOLFIRINOX administered intravenously. - The primary endpoints in clinical studies include progression-free survival, overall survival, and safety profile.

Other names

ABTL0812 in combination with FOLFIRINOXABTL-0812 in combination with FOLFIRINOXABTL 0812 in combination with FOLFIRINOX